Medivation, Inc. and Astellas Pharma achieved positive results based on interim analysis of the global Phase III PREVAIL trial of enzalutamide in more than 1,700 men with metastatic prostate cancer that has progressed despite androgen deprivation therapy and who have not yet received chemotherapy. The trial’s co-primary endpoints are overall survival and radiographic progression-free survival. An Independent Data Monitoring Committee concluded enzalutamide demonstrated a favorable benefit-...